AKT1 and sarcoma: (4) Phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) activation: while direct mechanistic evidence is lacking, dysregulation of this pathway in sarcomas (23, 24) may contribute to HGMS progression.